

Is the increasing cost of treating rare diseases sustainable?

Expert Opinion on Orphan Drugs

1, 581-583

DOI: [10.1517/21678707.2013.819289](https://doi.org/10.1517/21678707.2013.819289)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Illustrated operative management of spontaneous bleeding and compartment syndrome of the lower extremity in a patient with acquired hemophilia A: a case report. <i>Journal of Medical Case Reports</i> , 2014, 8, 132.	0.4	9
2	Pharmaceutical pricing, cost containment and new treatments for rare diseases in children. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 152.	1.2	3
3	World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients. <i>World Journal of Methodology</i> , 2014, 4, 163.	1.1	32
4	Orphan Drugs and Their Impact on Pharmaceutical Development. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 525-535.	4.0	43
5	Feasibility Study for Bedside Production of Recombinant Human Acid α -Glucosidase: Technical and Financial Considerations. <i>Current Pharmaceutical Biotechnology</i> , 2020, 21, 467-479.	0.9	1